Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events

Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other Events
Item 8.01 Other Events

Story continues below

On March4, 2019, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing the enrollment of the first patient in the Company’s MOMENTUM (Maximimizing Outcomes in Treating Acute Migraine) Phase 3 trial of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in migraine.

The full text of the press release is filed as Exhibit99.1 hereto and incorporated herein by reference.

Item 8.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release dated March4, 2019.

Axsome Therapeutics, Inc. Exhibit
EX-99.1 2 a19-5789_1ex99d1.htm EX-99.1 Exhibit 99.1     Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine   First patient enrolled in the MOMENTUM study   Trial being conducted under FDA Special Protocol Assessment (SPA)   Topline results anticipated in 1Q 2020   NEW YORK,…
To view the full exhibit click here

About Axsome Therapeutics,Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

An ad to help with our costs